Tess Romero's questions to ACADIA Pharmaceuticals Inc (ACAD) leadership • Q3 2024
Question
An analyst on behalf of Tess Romero of JPMorgan Chase & Co. asked for clarification on the statement that the Daybue launch has reached a 'steady state of new patient flow,' inquiring if this means steady net adds and what the strategy is to accelerate new patient starts.
Answer
CEO Catherine Owen Adams explained that after a strong initial launch burst, new patient additions have plateaued, which is common for rare disease launches. To re-accelerate growth, the strategy focuses on three areas: 1) better communicating the drug's efficacy by translating clinical scales into real-world benefits, 2) improving management of the early patient journey to enhance persistence, and 3) increasing penetration outside of Centers of Excellence (COEs), where 70% of patients are treated.